5 Pharmaceutical Stocks to Buy Now

by Portfolio Grader | October 5, 2012 4:55 pm

This week, five Pharmaceutical stocks are improving their overall rating on Portfolio Grader[1]. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).

Mylan (NASDAQ:MYL[2]) is bettering its rating of C (“hold”) from last week to a B (“buy”) this week. Mylan is a global generic and specialty pharmaceuticals company. In Portfolio Grader’s specific subcategories of Equity and Cash Flow, MYL also gets A’s. Shares of the company are up 4.4% from a month ago. This is better than the Nasdaq’s 2.4% for the same period. For more information, get Portfolio Grader’s complete analysis of MYL stock[3].

This week, Acura Pharmaceuticals (NASDAQ:ACUR[4]) pushes up from a C to a B rating. Acura Pharmaceuticals engages in the research, development, and manufacture of pharmaceutical product candidates utilizing its proprietary Aversion and Impede technologies. Shares of the company have shot up 9.5% over the past month. For more information, get Portfolio Grader’s complete analysis of ACUR stock[5].

This week, Watson Pharmaceuticals‘s (NYSE:WPI[6]) ratings are up from a C last week to a B. Watson develops, manufactures, markets, sells and distributes pharmaceutical products. Over the last month, the stock price went up 4.9%. For more information, get Portfolio Grader’s complete analysis of WPI stock[7].

Jazz Pharmaceuticals (NASDAQ:JAZZ[8]) shows solid improvement this week. The company’s rating rises from a C to a B. Jazz Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing products to meet medical needs in neurology and psychiatry. Shares of JAZZ have increased 30.7% over the past month. For more information, get Portfolio Grader’s complete analysis of JAZZ stock[9].

This week, BioDelivery Sciences (NASDAQ:BDSI[10]) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. BioDelivery Sciences is a specialty pharmaceutical company that is utilizing licensed and owned proprietary drug delivery technologies to develop and commercialize new formulations of proven therapeutics. Wall Street seems to agree with the upgrade and has propelled the stock up 37.5% over the past month. For more information, get Portfolio Grader’s complete analysis of BDSI stock[11].

Louis Navellier’s proprietary Portfolio Grader[1] stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here[12].

Source URL: https://investorplace.com/2012/10/5-pharmaceutical-stocks-to-buy-now-myl-acur-wpi/

---